UK Life Science Marketbeat Report

For the data behind the commentary, download the full Q2 2026 UK Life Sciences Report

Take-Up and Market Activity

Take-up across the Golden Triangle totalled 175,000 sf in Q2 2026, 8% below the five-year quarterly average, and 57% below the exceptional level recorded in Q1. London led leasing activity, accounting for over 56% of quarterly volume at 98,300 sf across five deals. The quarter's largest letting saw a confidential occupier take the entirety of Jahn Court in the Regent Quarter campus, comprising 85,500 sf of newly completed space.

Cambridge recorded 48,500 sf across three deals, while Oxford contributed 28,200 sf across two transactions.

The more significant signal lies in the volume of space currently under offer. At the close of Q2, 779,200 sf was under offer across the Golden Triangle, including 300,000 sf at Discovery Drive, Cambridge Biomedical Campus, under offer to GSK for its new global R&D centre. Should these transactions complete as expected, leasing activity in H2 2026 could return to the stronger levels recorded across the previous two quarters.

Rental Values

Prime quoting rents across the Golden Triangle held steady for the fifth consecutive quarter in Q2 2026. London commands £140.00 psf, Cambridge £77.00 psf, and Oxford £70.00 psf. All three markets are rated with an 'under pressure' outlook, reflecting the widening gap between quoting and achieved rents.

However, fitted space in Oxford is now commanding rents above previous benchmark levels in both Oxford and Cambridge. Across the Golden Triangle, the significant volume of space currently under offer suggests this gap could begin to narrow during the second half of 2026.

Supply and Pipeline

Four lab and lab-enabled schemes, totalling 352,500 sf, reached practical completion during Q2 2026. The largest was Merlin Place in the Cambridge North cluster at 139,200 sf, followed by Tech Foundry 3 at Harwell Science and Innovation Campus in Oxford at 69,500 sf, and Jahn Court in London's Regent Quarter at 85,500 sf, now fully let.

At the close of Q2 2026, 2.9 million sf of laboratory space remained under construction across the Golden Triangle, with 20% either pre-let or under offer. Approximately 2.2 million sf of speculative space is scheduled for delivery over the next three years. Development activity continues to moderate, with the volume under construction at its lowest level since Q1 2024.

A further 4.2 million sf has secured planning consent and could be delivered by 2029. In the near term, however, elevated construction and financing costs, geopolitical uncertainty, and higher vacancy rates are expected to constrain speculative development.

Venture Capital Investment

UK life sciences companies raised £2,005.2 million in venture capital in Q2 2026, the strongest quarter for VC investment in over a year, up 135% on Q1 and 102% above the five-year quarterly average.

The exceptional quarterly total was largely driven by Isomorphic Labs, a DeepMind spin-out that raised £1,550.7 million in late-stage funding. The company applies artificial intelligence to accelerate drug discovery, using advanced AI models to predict protein structure and behaviour, and to design novel therapeutics for pharmaceutical partners. Excluding all other transactions, this single funding round would represent the second-largest quarterly VC total recorded since the pandemic.

London accounted for £1,710.1 million, or 85% of all UK life sciences VC funding during the quarter. Cambridge followed with £209.9 million (10.5%), and Oxford secured £28.6 million (1.4%). Late-stage investment dominated, accounting for £1,834.3 million, or 91% of all capital raised, reflecting investors' continued preference for businesses with more established technologies and stronger clinical validation.

Investment Volumes and Yields

Investment volumes in the Golden Triangle life sciences real estate market reached £160 million across two transactions in Q2 2026. The largest was British Land's acquisition of the Life Sciences REIT portfolio for £150 million, comprising five properties across the Golden Triangle totalling 694,300 sf. Separately, Wrenbridge and Investec Realis acquired a three-acre site in North Cambridge from the Coulson Building Group for £10 million, with plans to develop it into a major commercial and life sciences hub.

Prime yields held steady at 5.00%. Secondary yields remain at 6.50% quarter-on-quarter, though the outlook for both has moved to 'outwards', reflecting geopolitical and macroeconomic headwinds. The Bank of England held the Bank Rate at 3.75% throughout Q2, with persistent inflationary pressures shifting market expectations away from near-term rate cuts.

Investment activity during H1 2026 reflects a challenging environment. While early signs of improving sentiment are emerging, expectations of a marked recovery in investor appetite should remain measured. Additional headwinds include geopolitical uncertainty, a selective VC funding environment, and elevated vacancy rates across key markets.

Market Outlook: The US IPO Window Reopens

US biotech public markets have strengthened significantly in 2026. The NASDAQ Biotechnology Index (NBI) recently reached an intraday high of 6,878.8 on 9 July 2026, up 47% over the previous 12 months and trading at levels not seen for approximately a decade. This reflects stronger investor sentiment, improved capital access, and resilient underlying biotech fundamentals.

The improvement in public markets is also helping to reopen the IPO window. Recent listings indicate that investors are once again willing to support high-quality life sciences companies with advanced clinical programmes and clear commercialisation pathways. For the Golden Triangle, the read-through is positive. Many of the region's leading businesses maintain US-facing investors, strategic partners, and potential NASDAQ pathways. A stronger US public market environment should support confidence toward later-stage UK companies and help sustain the pipeline of spinouts, start-ups, and scale-ups across London, Oxford, and Cambridge.

The real estate implications are expected to emerge gradually. Improved capital availability and stronger exit prospects should support occupier confidence, particularly among well-funded companies approaching clinical, commercial, or public market milestones. Activity is expected to remain focused on prime locations with established ecosystems.

Disclaimer: The views expressed in this report are provided for general informational purposes only and do not constitute investment advice or a solicitation.